파키스탄 칼슘 L-메틸폴레이트 공급업체 및 가격 — 마켓 오버뷰 2026

상위 제품

엽산

최종 업데이트

2026-06-23

서치 및 소싱 팀을 위한 핵심 요약

파키스탄의 칼슘 L-메틸폴레이트 마켓 인텔리전스 페이지에는 프리미엄 공급업체 0개가 포함되어 있습니다.
파키스탄에 대한 샘플 수출 거래 0건이 요약되어 있습니다.
파키스탄의 칼슘 L-메틸폴레이트에 대해 수출 파트너 기업 0개와 수입 파트너 기업 1개가 매핑되어 있습니다.
도매 샘플 항목: 0건; 산지가 샘플 항목: 0건.
수출 파트너 국가 0개와 수입 파트너 국가 0개가 랭킹되어 있습니다.
페이지 데이터 최종 업데이트일: 2026-06-23.

파키스탄의 칼슘 L-메틸폴레이트 수입 바이어 인텔리전스 및 가격 시그널: 바이어, 수요, 거래 파트너

파키스탄의 칼슘 L-메틸폴레이트에 대해 수입 파트너 기업 1개가 추적됩니다. 수출업체와 수입업체는 Supply Chain Intelligence 회사 프로필 및 분석을 활용해 바이어 수요, 파트너 밀도, 다운스트림 채널을 분석할 수 있습니다.

스캐터 포인트는 전체 거래 데이터셋의 100.0%에서 샘플링되었습니다.

칼슘 L-메틸폴레이트의 파키스탄 샘플 수입 거래 및 가격 기록

파키스탄의 칼슘 L-메틸폴레이트 샘플 수입 거래 5건은 가격 수준과 수요 측 거래 패턴 벤치마킹을 위한 날짜, 원산지, 무역 국가 맥락을 제공합니다.

파키스탄의 칼슘 L-메틸폴레이트 샘플 수입 거래 단가(일자별): 2025-12-11: 377.56 USD / kg, 2025-10-03: 223.33 USD / kg, 2025-10-03: 223.33 USD / kg, 2025-10-03: 223.33 USD / kg, 2025-08-14: 131.53 USD / kg.

일자	신고 품목	단가	수출업체	수입업체	원산지
2025-12-11	254***** *** ******	377.56 USD / kg	(-)	(-)	-
2025-10-03	324******* * *** *** ** * ****	223.33 USD / kg	(-)	(-)	-
2025-10-03	324******* * *** *** ** * ****	223.33 USD / kg	(-)	(-)	-
2025-10-03	324******* * *** *** ** * ****	223.33 USD / kg	(-)	(-)	-
2025-08-14	798******* * *** *** ** * ****	131.53 USD / kg	(-)	(-)	-

파키스탄 내 상위 칼슘 L-메틸폴레이트 바이어, 수입업체 및 수요 파트너

선도 바이어 프로필을 검토하고 파키스탄의 칼슘 L-메틸폴레이트에 대해 추적되는 전체 수입 파트너 기업 1개와 비교하세요. 수출업체와 수입업체는 Supply Chain Intelligence 회사 프로필 및 분석으로 수요 측 파트너 적합도를 평가할 수 있습니다.

(파키스탄)

최근 수입 거래: 2025-06-27

임직원 규모: 직원 501 - 1000명

산업군: 음료 제조식품 제조식음료 서비스업

밸류체인 역할: 유통 / 도매식품 제조

파키스탄 수입 파트너 커버리지

1개 기업

수입 파트너 기업 수는 파키스탄의 칼슘 L-메틸폴레이트 수요 측 가시성을 보여줍니다.

공급망 인텔리전스 분석과 기업 프로필을 활용해 파키스탄에서 활동 중인 칼슘 L-메틸폴레이트 수입업체, 유통업체, 바이어 네트워크를 식별하세요.

Classification

Product TypeIngredient

Product FormBulk ingredient (crystalline powder / dry crystalline or microencapsulated forms)

Industry PositionNutraceutical / Health & OTC ingredient

Market

Calcium L-methylfolate (calcium L-5-methyltetrahydrofolate; levomefolate calcium) is a folate (vitamin B9) ingredient used in dietary supplements and, depending on classification, therapeutic goods. In Pakistan, availability is expected to be import-driven and market access is highly sensitive to correct regulatory classification and importer authorization for therapeutic goods and Health & OTC products/raw materials under DRAP processes. International quality references exist via FAO/WHO JECFA specifications and USP dietary supplement monographs, which can anchor assay and impurity expectations. Clearance commonly depends on complete import documentation and use of Pakistan Customs electronic filing, plus DRAP e-systems where the item falls under DRAP purview.

Market RoleImport-dependent supplement ingredient market

Specification

Physical Attributes

White to light yellowish, almost odourless, crystalline powder (FAO/WHO JECFA specification).
Sparingly soluble in water; very slightly soluble or insoluble in most organic solvents; soluble in alkaline solutions (FAO/WHO JECFA specification).

Compositional Metrics

Assay: 95.0–102.0% (anhydrous basis) in FAO/WHO JECFA specifications.
Diastereomer/related-substances controls referenced in specifications (e.g., D-5-methylfolate limit) (FAO/WHO JECFA; USP monograph preview shows NMT 1.0% calcium D-5-methyltetrahydrofolate).
Lead limit and microbiological limits are specified in FAO/WHO JECFA specifications (e.g., lead NMT 2 mg/kg; total viable aerobic count NMT 1000 CFU/g).

Packaging

Buyer/importer specifications commonly require a manufacturer Certificate of Analysis (COA) aligned to recognized standards (e.g., FAO/WHO JECFA specifications and/or USP dietary supplement monograph references), plus lot identification for traceability.

Supply Chain

Value Chain

Overseas manufacturer → Pakistan commercial importer (authorized where DRAP-regulated) → customs filing/clearance (Pakistan Customs electronic systems) → DRAP import permission/clearance workflow when applicable → distribution to local supplement/pharma formulators → finished product manufacturing and domestic distribution.

Freight IntensityLow

Transport ModeMultimodal

Risks

Regulatory Compliance HighMisclassification or lack of required DRAP authorization/import permissions for therapeutic goods and Health & OTC products/raw materials can result in detention, refusal of entry, or extended clearance delays at import, disrupting supply to local supplement/pharma manufacturers.Confirm whether the specific item/strength/use-case is treated as a DRAP-regulated therapeutic good or Health & OTC raw material; ensure the importer has the appropriate DRAP authorization and obtain required DRAP import clearance (OIES/PSW release order where applicable) before shipment.

Documentation Gap MediumIncomplete or inconsistent import documents (e.g., invoice, packing list, certificate of origin, LC/insurance where used) can delay customs processing and clearance, increasing dwell time and disrupting production schedules.Run a pre-shipment document reconciliation (invoice ↔ packing list ↔ COA ↔ Goods Declaration data) and ensure all required documents are prepared for electronic submission.

Quality MediumRisk of substandard material or off-spec impurity/contaminant levels can trigger rejection by buyers or regulatory action; DRAP states it denies entry of therapeutic goods that do not comply with regulatory requirements to prevent infiltration of substandard/suspected falsified products.Source from qualified manufacturers and require COA aligned to recognized specifications (e.g., FAO/WHO JECFA and/or USP dietary supplement monograph references); consider independent third-party testing for identity, assay, heavy metals, and microbial limits per agreed specification.

Logistics LowAlthough the product is not freight-bulky, port/clearance lead-time variability can create stockout risk for formulators if import permissions and electronic release steps are not synchronized with shipping schedules.Build lead-time buffers around DRAP permission steps and customs electronic processing; maintain safety stock for critical formulations.

FAQ

Does importing calcium L-methylfolate into Pakistan require DRAP approval?If the product is handled as a DRAP-regulated therapeutic good or as a Health & OTC (nutraceutical) product/raw material, DRAP indicates importers must follow its import authorization and clearance processes via its e-systems (including OIES and, for DIL-linked clearances in some contexts, PSW electronic release orders).

Which core documents are typically required for imports into Pakistan?Commonly cited required documents include bills of lading, invoices, packing lists, certificates of origin, copies of letters of credit, and insurance certificates. For regulated health/therapeutic supply chains, buyers and regulators also commonly expect a manufacturer Certificate of Analysis (COA) and any required DRAP import permissions.

What internationally recognized specifications can be used to anchor quality checks for calcium L-5-methyltetrahydrofolate?FAO/WHO JECFA publishes specifications for calcium L-5-methyltetrahydrofolate (including assay and limits for certain impurities/contaminants), and USP provides a dietary supplement monograph reference for calcium l-5-methyltetrahydrofolate that can be used as an additional quality anchor in supplier qualification and COA review.